Adicet Bio, Inc.

Adicet Bio, Inc.

ACET·NASDAQ

$8.15

+4.1%
HealthcareBiotechnology

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

At a Glance

Live Snapshot
Market Cap$76.19M
EPS-16.9500
P/E Ratio-0.48
Earnings Date08/06/2026

acet

Additional Paid-In Capital

Last Annual Value

773.79M

3-Year CAGR

13%

5-Year CAGR

29%

10-Year CAGR

%

Adicet Bio, Inc.

Adicet Bio, Inc. Competitors Analysis of Additional Paid-In Capital

ACET · NASDAQ
CompanyAdditional Paid-In Capital
CAGR 3Y
CAGR 5Y
CAGR 10Y
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
773.79M
12.0%10.4%N/A 
119.14M
17.7%16.4%N/A
421.10M
-0.7%2.7%N/A
1.14B
4.3%3.4%10.7%
748.72M
3.5%5.8%N/A
565.72M
197.2%110.3%N/A
IMA logo
ImageneBio Inc
NASDAQ:IMA
363.09M
-7.1%0.5%N/A
1.04B
2.3%20.2%N/A
512.91M
4.4%5.7%N/A
627.98M
16.4%19.9%N/A
387.25M
17.7%225.9%N/A
Adicet Bio, Inc.

Adicet Bio, Inc. Fair Value Envelope

ACET · NASDAQ

Our analysis suggests that ACET has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $8.15, this represents a potential HIDDEN relative to our calculated worth for Adicet Bio, Inc..

Intrinsic Value
Current Price: $8.15